AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
AC Immune SA
XNAS · usd
SIC 8731 · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
FIGI BBG00D0RHJ65
2.42▼ 0.08 (-3.20%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
2.50
Day's Range
2.40 – 2.48
52-Week Range
2.10 – 4.00
Volume
139.5K
Avg Volume
179.2K
Share Statistics
Shares Outstanding
Employees
122
Exchange
XNAS
Listed
2016-09-23
Share count as of December 31, 2025

AC Immune SA (ACIU) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about AC Immune SA (ACIU)
What is AC Immune SA's Market Cap?
AC Immune SA's Market Cap is $246.2M, based on as-reported figures from SEC (XBRL) filings.
What is AC Immune SA's Enterprise Value?
AC Immune SA's Enterprise Value is $211.9M, based on as-reported figures from SEC (XBRL) filings.
What is AC Immune SA's Price / Sales?
AC Immune SA's Price / Sales is 11.3×, based on as-reported figures from SEC (XBRL) filings.
What is AC Immune SA's EV / Revenue?
AC Immune SA's EV / Revenue is 9.8×, based on as-reported figures from SEC (XBRL) filings.
What is AC Immune SA's Revenue (TTM)?
AC Immune SA's Revenue (TTM) is $21.7M, based on as-reported figures from SEC (XBRL) filings.
What is AC Immune SA's Net Income (TTM)?
AC Immune SA's Net Income (TTM) is -$54.1M, based on as-reported figures from SEC (XBRL) filings.
What is AC Immune SA's Diluted EPS (TTM)?
AC Immune SA's Diluted EPS (TTM) is -0.53, based on as-reported figures from SEC (XBRL) filings.
What is AC Immune SA's Net Debt?
AC Immune SA's Net Debt is -$34.3M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ACIUAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of CHF, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2025Jun 30, 2024Jun 30, 2023Jun 30, 2022
Revenue
Contract revenue
Total revenue
Operating expenses
Research & development expenses
General & administrative expenses
Other operating income/(expense), net
Total operating expenses
Operating loss
Financial income
Financial expense
Exchange differences
Finance result, net
Loss before tax
Loss for the period
Loss per share:
Basic loss per share for the period attributable to equity holders
Diluted loss per share for the period attributable to equity holders